Kenichi Taguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenichi Taguchi has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Kuniaki Sato
Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
24 shared publications - Muneyuki Masuda
National Hospital Organization Kyushu Cancer Center 4 Department of Head and Neck Surgery Fukuoka, Japan
24 shared publications - Takashi Nakagawa
Kyushu University 2 Department of Otorhinolaryngology, Graduate School of Medical Sciences Fukuoka, Japan
24 shared publications - Jorge Silvio Gutkind
Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
23 shared publications - Koshi Mimori
Department of Surgery Kyushu University Beppu Hospital Oita Japan
23 shared publications - Noritaka Komune
Department of Otorhinolaryngology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
23 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Correlation between PITX2 and YAP expression in EACSCC tissues.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Correlation between PITX2 and YAP expression in EACSCC tissues.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Clinical data for EACSCC patients enrolled in RNA-seq analysis in Figure 1.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Clinical data for EACSCC patients enrolled in RNA-seq analysis in Figure 1.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Transcriptomic distances and gene ontology analysis in EACSCC and Skin tissues.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Transcriptomic distances and gene ontology analysis in EACSCC and Skin tissues.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Super Enhancer formation and YAP bindings in EACSCC and Skin tissues.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Super Enhancer formation and YAP bindings in EACSCC and Skin tissues.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Multivariate analyses of YAP and PITX2 expression with clinicopathological factors for overall survival in the EACSCC patients in Figure 5.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Multivariate analyses of YAP and PITX2 expression with clinicopathological factors for overall survival in the EACSCC patients in Figure 5.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
The effect of TEAD inhibition and PITX2 knockdown in EACSCC and HNSCC cells in vitro.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
The effect of TEAD inhibition and PITX2 knockdown in EACSCC and HNSCC cells in vitro.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Single sample GSEA analysis in EACSCC and Skin tissues.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Single sample GSEA analysis in EACSCC and Skin tissues.
- Open Access
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Primer sequences for qPCR in Figure 3C.
- 5 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Primer sequences for qPCR in Figure 3C.
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Transcriptomic analysis revealed hyperactivation of YAP signaling in EACSCC. A, Schematic representation of the experimental design of RNA-seq in EACSCC and noncancerous skin tissues. B, PCA for the RNA-seq data derived from EACSCC (n = 17) and noncancerous skin tissues (n = 8). C, Volcano plot representing DEGs between EACSCC and noncancerous skin tissues. D, GO analysis for the DEGs upregulated in EACSCC in the Molecular Signature Database (MSigDB) Hallmark pathways. E, GSEA representing gene sets positively or negatively enriched in EACSCC compared with noncancerous skin tissues in MSigDB Hallmark pathways. F, GSEA enrichment plots for the indicated YAP/TAZ-TEAD transcriptional target gene sets showing the enrichment between EACSCC and noncancerous skin tissues (left). Violin plots for ssGSEA scores for each group (right). G, The heatmap and hierarchical clustering for the selected genes in the indicated pathways. Gene expression levels were scaled among samples for each gene. The ssGSEA scores for the TEAD inhibitor target signature (Sato and colleagues; ref. 23) are shown at the top of the heatmap. H, Waterfall plots showing the predicted TF activities in EACSCC. I, Kaplan–Meier overall survival curves for the patients with EACSCC with TEAD inhibitor target signature high or low scores calculated by ssGSEA. PC, principal component. [A, Created in BioRender. Sato, K. (2026) https://BioRender.com/gwd1391.]
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
Transcriptomic analysis revealed hyperactivation of YAP signaling in EACSCC. A, Schematic representation of the experimental design of RNA-seq in EACSCC and noncancerous skin tissues. B, PCA for the RNA-seq data derived from EACSCC (n = 17) and noncancerous skin tissues (n = 8). C, Volcano plot representing DEGs between EACSCC and noncancerous skin tissues. D, GO analysis for the DEGs upregulated in EACSCC in the Molecular Signature Database (MSigDB) Hallmark pathways. E, GSEA representing gene sets positively or negatively enriched in EACSCC compared with noncancerous skin tissues in MSigDB Hallmark pathways. F, GSEA enrichment plots for the indicated YAP/TAZ-TEAD transcriptional target gene sets showing the enrichment between EACSCC and noncancerous skin tissues (left). Violin plots for ssGSEA scores for each group (right). G, The heatmap and hierarchical clustering for the selected genes in the indicated pathways. Gene expression levels were scaled among samples for each gene. The ssGSEA scores for the TEAD inhibitor target signature (Sato and colleagues; ref. 23) are shown at the top of the heatmap. H, Waterfall plots showing the predicted TF activities in EACSCC. I, Kaplan–Meier overall survival curves for the patients with EACSCC with TEAD inhibitor target signature high or low scores calculated by ssGSEA. PC, principal component. [A, Created in BioRender. Sato, K. (2026) https://BioRender.com/gwd1391.]
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
YAP and PITX2 predict poor prognosis of patients with EACSCC. A, Representative images of immunohistochemical staining for YAP in EACSCC tissues. B and C, Kaplan–Meier curves for overall survival (B) and progression-free survival of patients with EACSCC classified according to the YAP expression levels. D, Representative images of immunohistochemical staining for PITX2 in EACSCC tissues. E and F, Kaplan–Meier curves for overall survival (B) and progression-free survival of patients with EACSCC classified according to the PITX2 expression levels. P values were calculated using the log-rank test.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
YAP and PITX2 predict poor prognosis of patients with EACSCC. A, Representative images of immunohistochemical staining for YAP in EACSCC tissues. B and C, Kaplan–Meier curves for overall survival (B) and progression-free survival of patients with EACSCC classified according to the YAP expression levels. D, Representative images of immunohistochemical staining for PITX2 in EACSCC tissues. E and F, Kaplan–Meier curves for overall survival (B) and progression-free survival of patients with EACSCC classified according to the PITX2 expression levels. P values were calculated using the log-rank test.